13D Filing: Armistice Capital and Cerecor Inc (CERC)

Page 7 of 10

Page 7 of 10 – SEC Filing

Item 5.
Interest in Securities of the Issuer.
(a) – (d)
As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 3,210,000 Shares, constituting 22.8% of the Shares, based upon 14,081,453 Shares outstanding as of the date hereof.  Each of the Reporting Persons has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 3,210,000 Shares.  Each of the Reporting Persons has the sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 3,210,000 Shares.  Other than the Shares acquired pursuant to the Securities Purchase Agreement (as summarized in Item 4 above), all Shares beneficially owned by the Reporting Persons were purchased in open market transactions.
The transactions in the Shares by the Reporting Persons during the past sixty days are set forth on Exhibit B.
(e)
N/A
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described in Item 4 above and/or incorporated herein by reference.
Item 7.
Material to be Filed as Exhibits.
Exhibit A:          Joint Filing Agreement
Exhibit B:          Schedule of Transactions in the Shares
Exhibit C:          Press Release of Cerecor Inc., dated April 28, 2017 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit D:          Securities Purchase Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit E:          Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Cerecor Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit F:          Registration Rights Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 7 of 10